A pilot randomised controlled trial of topical St John’s Wort in the treatment of post-herpetic neuralgia

niversity of Technology Sydney0 个研究点目标入组 60 人开始时间: 2015年9月25日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Any person male or female aged 18-65 presenting with a confirmed diagnosis of herpetic neuralgia.
•- Willingness to give written informed consent and willingness to participate to and comply with the study (and who do not meet exclusion criteria – see below).

•- Other infectious skin diseases
•- Diagnosed hepato-bilary disease/inflammation
•- Current or < 6 month substance abuse disorder including alcohol
•- Current or < 12 month use of St. John’s wort
•- Current or < 1 month of therapeutic agents with narrow therapeutic windows (e.g. warfarin, anti-retroviral mediciations)
•- Previous reaction to St. John’s wort
•- Medications that maybe pharmacokinetically altered via St. John’s wort including: amitriptyline, anti-coagulants e.g. phenprocoumon, warfarin, anti-fugals e.g. voriconazole, anti-histamines e.g. fexofenadine, benzodiazepines e.g. alprazolam, Chemotherapeutics e.g. irinotecan, digoxin, HIV medication (anti-retrovirals), Immunosuppressants e.g. cyclosporine, methadone, OCP, statins e.g. simvastatin, warfarin (Henderson 2002; Izzo 2004). However this interactions are based on case studies and theoretical interactions and are regarded to be induced by hyperforin (a constituent of St. John’s wort); low or non-standardised hyperforin preparations are regarded to not induce drug interactions as little induction of P-glycoprotein and CYP P450 enzymes occurs (Madabushi et al. 2006).
•- Non-English speakers.
•- More than 6 months since the onset of acute herpetic rash

发起方

niversity of Technology Sydney